BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Scientists are getting our robotic explorers ready to help send humans to Mars - 2Whale stranded off Germany for days found stuck again
- 3Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- 4The many ways that baking is winter therapy. With a delicious ending
- 5White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Parents who delay baby's first vaccines also likely to skip measles shots
- Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- The Most Important Crossroads in Olympic History
- From Dread to Certainty: Individual Accounts of Strengthening
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- Lego's $650 Pokémon set is already sold out as demand, preorders surge
